Lost Money on Fiserv, Inc. (FI)? Contact Levi & Korsinsky to Join Class Action Before September 22, 2025
https://zlk.com/pslra-1/fiserv-inc-lawsuit-submission-form?prid=159125&wire=5&utm_campaign=20
or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) 363-7500 to speak to our team of experienced shareholder advocates.
THE LAWSUIT: A class action securities lawsuit was filed against Fiserv, Inc. that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between July 24, 2024 and July 22, 2025.
CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (a) Due to cost issues and other problems with its older point-of-sale platform, Payeezy, Fiserv forced Payeezy merchants to convert to its Clover platform; (b) Clover's revenue growth and GPV growth were temporarily boosted by these conversions, which concealed a slowdown in new merchant business; (c) shortly after these conversions, a significant portion of former Payeezy merchants switched to competing solutions due to Clover's high pricing, inadequate customer service, and other issues; (d) as a result of these merchant losses, Clover's GPV growth was significantly slowing, and its revenue growth was unsustainable; and (e) based on the foregoing, Fiserv's positive class period statements about Clover growth strategies, competition, attrition, GPV growth, and business prospects were materially false and misleading.
WHAT'S NEXT? If you suffered a loss in Fiserv, Inc. stock during the relevant time frame - even if you still hold your shares - go to https://zlk.com/pslra-1/fiserv-inc-lawsuit-submission-form?prid=159125&wire=5&utm_campaign=20 to learn about your rights to seek a recovery. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
44 minutes ago
- Globe and Mail
Strategy Announces $4.2 Billion Stock Sales Agreement
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Strategy ( (MSTR)) has shared an announcement. On July 31, 2025, Strategy announced a sales agreement with several agents to issue and sell shares of its Variable Rate Series A Perpetual Stretch Preferred Stock, with an aggregate offering price of up to $4.2 billion. The company plans to use the proceeds for general corporate purposes, including the acquisition of Bitcoin and working capital. The sales will be conducted as an 'at the market offering' and are subject to terms and conditions outlined in the sales agreement. This move is part of Strategy's broader strategy to leverage its position in the digital asset market and enhance its financial flexibility. The most recent analyst rating on (MSTR) stock is a Buy with a $392.00 price target. To see the full list of analyst forecasts on Strategy stock, see the MSTR Stock Forecast page. Spark's Take on MSTR Stock According to Spark, TipRanks' AI Analyst, MSTR is a Neutral. The overall stock score of 48 reflects significant financial and valuation challenges, with high leverage and negative earnings outweighing positive strategic initiatives and Bitcoin-focused capital strategies. Despite a strong strategic focus on cryptocurrency and recent successful capital raising, the financial instability and legal risks pose substantial concerns. To see Spark's full report on MSTR stock, click here. More about Strategy MicroStrategy Incorporated, doing business as Strategy, is a publicly traded company recognized as the world's first and largest Bitcoin Treasury Company. It has adopted Bitcoin as its primary treasury reserve asset and strategically accumulates Bitcoin through equity and debt financings, as well as cash flows from operations. The company also provides AI-powered enterprise analytics software, integrating analytics expertise with digital asset growth, positioning itself as a leader in both the digital asset and enterprise analytics sectors. Average Trading Volume: 12,259,375 Technical Sentiment Signal: Buy Current Market Cap: $111.9B See more data about MSTR stock on TipRanks' Stock Analysis page.
CBC
2 hours ago
- CBC
Lawyer breaks down legal fight over Trump's tariffs
U.S. President Donald Trump's use of emergency powers to impose across-the-board tariffs on trading partners came under sharp questioning from federal appellate court judges. Robert Glasgow, partner with McCarthy Tetrault LLP, talks about the legal challenges to Trump's authority to impose tariffs.
Globe and Mail
2 hours ago
- Globe and Mail
AstraZeneca's AZD3427 Study: A Potential Game-Changer for Heart Failure and Pulmonary Hypertension
AstraZeneca ((AZN)), Parexel International ((PRXL)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. AstraZeneca, in collaboration with Parexel International, is conducting a Phase IIb study titled A Phase IIb Randomised, Double-blind, Placebo-controlled, Multi-centre, Dose-ranging Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Due to Left Heart Disease (WHO Group 2). The study aims to assess the efficacy of AZD3427 in reducing pulmonary vascular resistance in patients with heart failure and pulmonary hypertension over 24 weeks, highlighting its potential significance in treating these conditions. The intervention being tested is AZD3427, administered as a subcutaneous injection. It is designed to target pulmonary hypertension by reducing vascular resistance, with the study evaluating three different dose levels of the drug. The study follows a randomized, parallel assignment model with triple masking, involving participants, care providers, and investigators. Its primary purpose is treatment-focused, aiming to determine the optimal dosing strategy for AZD3427. The study began on April 24, 2023, with an estimated completion date in July 2025. These timelines are crucial for tracking the progress and potential market introduction of AZD3427. The outcome of this study could significantly impact AstraZeneca's market position, potentially boosting its stock performance if results are positive. Investors will be keenly watching for updates, especially in the context of competitive treatments for heart failure and pulmonary hypertension. The study is ongoing, with further details available on the ClinicalTrials portal.
